Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?

BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100.

We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at fool.com →

More in Finance & Markets

More from Thursday 8 October →